Better Biopharma
“How can biopharma improve?” This question is the guiding ethos of the Better Biopharma podcast. Through conversations with experts across the biopharma landscape, host Tyler Menichiello explores the work being done to make better medicines and optimize manufacturing. Each episode is a dive into the guest's methods, their curiosity, and their determination. By shining a light on the visionaries pushing the industry forward, Better Biopharma aims to inform and inspire their peers to continue doing the same.
Episodes
33 episodes
2026 Regulatory Updates And Operation TrialBlazer
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by former FDA staffers Eva Temkin, partner at Arnold & Porter, and Elizabeth Trentacost, senior associate at Arnold & Porter. They reflect on 2026 regulatory develo...
Focusing On Quality Unit Independence With Tatyana Matveeva, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tatyana Matveeva, Ph.D., an expert in cGMP manufacturing and regulatory compliance. They discuss cell and gene therapy (CGT) manufacturing and the importance of maintain...
Developing Multi-Targeted T-Cell Engagers With Deck Bio’s Johanna Kaufmann
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Deck Bio’s chief scientific officer, Johanna Kaufmann, to discuss the company’s multi-peptide-MHC-targeted T-cell engager platform for solid tumors. Kaufmann explains th...
Fixing AAV Recovery With Siren Biotechnology’s Nathalie Clément, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nathalie Clément, Ph.D., Siren Biotechnology’s SVP of vector development. The two discuss the historical challenges of purifying AAV vectors and the developments that ha...
Digitalizing The Biopharma Ecosystem With Kat Kozyrytska
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Kat Kozyrytska, a technology advisor and portfolio strategy leader. Kozyrytska shares her thoughts on how technology companies fit into the broader biopharma ecosystem. ...
Modulating Multispecific Manufacturability With AP Biosciences’ JJ You, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Jhong-Jhe You, Ph.D., VP of antibody discovery at AP Biosciences. You explains how molecular complexity and aspects of antibody design can influence a product’s manufact...
The Facility Master Planning Playbook With Herman Bozenhardt
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by friend-of-the-show Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and r...
Cell Therapy Without The Cells: Building A Therapeutic Secretome With Noveome Biotherapeutics’ Larry Brown, Sc.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Larry Brown, Sc.D., chief scientific officer at Noveome Biotherapeutics, to discuss ST266, a first-of-its-kind secretome therapy. This cell-free biologic is essentially ...
The Editors’ Roundtable: A Midyear Look At The 2026 Life Sciences Industry
In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by chief editors from across the Life Science Connect ecosystem to discuss what’s shaping the pharmaceutical industry in 2026. The editors reflect on recent develop...
Validation Challenges Facing Advanced Single-Use Technologies
In this episode of "Better Biopharma," host Tyler Menichiello is joined by BioPlan Associates’ director of research, Katrina Cordovado, as well as Joshua Nelson, Ph.D., a senior material qualification specialist at Takeda, and Paul Priebe, a co...
Aligning Upstream And Downstream Development (Part 2)
In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Pro...
Aligning Upstream And Downstream Development (Part 1)
In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process D...
Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and ...
Scaling Regenerative Medicine Production With PolarityBio’s Nikolai Sopko, MD, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nikolai Sopko, MD, Ph.D., chief operating officer, chief scientific officer, and director at PolarityBio, a biotech company developing SkinTE, an investigational autolog...
Pursuing Quality While Maintaining Process Control With Richard Moroney, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Richard Moroney, Ph.D., managing director at Stat Consulting. Moroney shares his thoughts on how organizations should think about and approach process control. His philo...
Unlocking The Therapeutic Power Of Fibroblasts With Pete O’Heeron And Hamid Khoja, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of con...
Supporting The Bioprocessing Workforce In The AI Era With Sanofi's Eric Doerr
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Eric Doerr, a drug substance technical lead in the manufacturing science and technology (MSAT) group at Sanofi. The two discuss how the industry can support the next gen...
Putting Pressure On CDMOs With Herman Bozenhardt
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and regulatory complianc...
Data Governance And Regulations For AI Use In GMP With Peter Baker
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Peter Baker, former FDA investigator and president of Live Oak Quality Assurance. They discuss Annex 22, the EMA’s GMP annex addressing the use of artificial intelligenc...
The Editors’ Roundtable: A 2025 Retrospective Of The Life Science Industry
In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by fellow chief editors from across the Life Science Connect ecosystem to reflect on the year and share their industry outlooks for 2026. This editorial roundtable ...
Combining AI With Operations Research To Advance Biomanufacturing With Tinglong Dai, Ph.D., and Tugce Martagan, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tinglong Dai, Ph.D., Bernard T. Ferrari Professor of Business at Johns Hopkins University, and Tugce Martagan, Ph.D., associate professor at Northeastern University, to ...
Building An Oral Vaccine Platform With Vaxart's Sean Tucker, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines. They discuss Vaxart’s manufacturing process and ...
Lessons In Scaling Regenerative Medicine Manufacturing With Organogenesis's Patrick Bilbo
In this episode of "Better Biopharma," Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products. They discuss the construct...
Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics' Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D.
In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of develop...
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peri...